157 related articles for article (PubMed ID: 35875063)
1. Characteristics, Treatment Complexity, and Outcome of Mixed-Phenotype Acute Leukemia in Children in a Low-Middle-Income Country.
Salama M; Ahmed S; Soliman S; El-Sharkawy N; Salem S; El-Nashar A; Khedr R; Lehmann L; Sidhom I; El-Haddad A
Front Oncol; 2022; 12():941885. PubMed ID: 35875063
[TBL] [Abstract][Full Text] [Related]
2. [Clinical characteristics and prognosis of 34 cases of acute myeloid leukemia with FLT3 internal tandem duplication and MLL gene rearrangement].
Zhou JR; Zhang X; Zhao YL; Yang JF; Zhang JP; Cao XY; Lu Y; Liu DY; Lyu FY; Ouyang J; Lu PH
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):751-756. PubMed ID: 30369187
[No Abstract] [Full Text] [Related]
3. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
[TBL] [Abstract][Full Text] [Related]
4. Outcome of Childhood Acute Myeloid Leukemia With FLT3-ITD Mutation: The Experience of Children's Cancer Hospital Egypt, 2007-17.
Semary SF; Hammad M; Soliman S; Yassen D; Gamal M; Albeltagy D; Hamdy N; Mahmoud S
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e529-e541. PubMed ID: 32473792
[TBL] [Abstract][Full Text] [Related]
5. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of induction efficacy and prognostic factors in FLT3-ITD positive acute myeloid leukemia in the real world].
Jia JS; Zhu HH; Gong LZ; Zhao T; Wang J; Jiang Q; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):398-403. PubMed ID: 31207705
[No Abstract] [Full Text] [Related]
7. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
8. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of pediatric acute myeloid leukemia patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era.
Choi S; Kim BK; Ahn HY; Hong KT; Choi JY; Shin HY; Kang HJ
Blood Res; 2020 Dec; 55(4):217-224. PubMed ID: 33232940
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and Outcome of FLT3-ITD-Positive Pediatric Acute Myeloid Leukemia-Experience of Polish Pediatric Leukemia and Lymphoma Study Group from 2005 to 2022.
Czogała M; Czogała W; Pawińska-Wąsikowska K; Książek T; Bukowska-Strakova K; Sikorska-Fic B; Łaguna P; Fałkowska A; Drabko K; Muszyńska-Rosłan K; Krawczuk-Rybak M; Kozłowska M; Irga-Jaworska N; Zielezińska K; Urasiński T; Bartoszewicz N; Styczyński J; Skalska-Sadowska J; Wachowiak J; Rodziewicz-Konarska A; Kałwak K; Ciebiera M; Chaber R; Mizia-Malarz A; Chodała-Grzywacz A; Karolczyk G; Bobeff K; Młynarski W; Mycko K; Badowska W; Tomaszewska R; Szczepański T; Machnik K; Zamorska N; Balwierz W; Skoczeń S
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760526
[TBL] [Abstract][Full Text] [Related]
11. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
Kottaridis PD; Gale RE; Frew ME; Harrison G; Langabeer SE; Belton AA; Walker H; Wheatley K; Bowen DT; Burnett AK; Goldstone AH; Linch DC
Blood; 2001 Sep; 98(6):1752-9. PubMed ID: 11535508
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
14. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ
Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276
[TBL] [Abstract][Full Text] [Related]
15. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
16. [Clinical features and prognostic factors in adult acute myeloid leukemia patients with FLT3-ITD and CEBPA gene co-mutation].
Pei RR; Zhang RH; Yu JF; Jiang ZX; Sun H; Wan DM; Xie XS; Liu YF; Li T; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):297-301. PubMed ID: 32447933
[No Abstract] [Full Text] [Related]
17. Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns.
Guan W; Zhou L; Li Y; Yang E; Liu Y; Lv N; Fu L; Ding Y; Wang N; Fang N; Liu Q; Wang B; Li F; Zhang J; Wang M; Wang L; Jing Y; Li Y; Yu L
Exp Hematol Oncol; 2021 Apr; 10(1):27. PubMed ID: 33836835
[TBL] [Abstract][Full Text] [Related]
18. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
19. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
Xu LW; Su YZ; Tao HF
Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of FLT3-ITD in pediatric acute myeloid leukemia: a meta-analysis of cohort studies.
Wu X; Feng X; Zhao X; Ma F; Liu N; Guo H; Li C; Du H; Zhang B
Mol Cell Biochem; 2016 Sep; 420(1-2):121-8. PubMed ID: 27435859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
